Showing 653 results

Filters Content type: News, Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

NICE recommends Victrelis in speedy review

Editor's pick
InPharm
9 March 2012
Hepatitis C treatment

GS-7977 plus ribavirin rapidly suppresses HCV but most patients relapse

News
7 March 2012
Hepatitis C treatment

Telaprevir and boceprevir boost sustained response rates for HIV/HCV coinfected

News
7 March 2012
New & experimental hepatitis C treatment

Good 12-Week HCV Suppression with Oral Telaprevir/VX-222/Ribavirin Combo

Editor's pick
HIVandHepatitis.com
27 February 2012
New & experimental hepatitis C treatment

European Medicines Agency informs doctors and patients about drug interaction between Victrelis and ritonavir-boosted HIV protease inhibitors

Editor's pick
European Medicines Agency
18 February 2012
New & experimental hepatitis C treatment

HCAB position statement: Hepatitis C drug development and drug-drug interaction studies

Editor's pick
EATG
18 February 2012
New & experimental hepatitis C treatment

Hard-to-Treat Group Trips Up Hepatitis C Drug

Editor's pick
MedPage Today
18 February 2012
New & experimental hepatitis C treatment

Gilead Drops as Patients Relapse on Hepatitis C Drug

Editor's pick
Bloomberg Business Week
17 February 2012
New & experimental hepatitis C treatment

Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study

Editor's pick
Gilead press release
17 February 2012
New & experimental hepatitis C treatment

Drugmakers Jockey for Piece of Future Hepatitis C Combo Pill

Editor's pick
Bloomberg Business Week
15 February 2012
New & experimental hepatitis C treatment

Gilead, Vertex and the Mystery of Missing Hep C Patients

Editor's pick
The Street
13 February 2012
Drug interactions & pharmacokinetics

Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels

Editor's pick
HIVandHepatitis.com
7 February 2012
New & experimental hepatitis C treatment

Gilead Gains on Positive Data From Experimental Hepatitis C Drug

Editor's pick
Bloomberg
3 February 2012
Pharmaceutical industry

Top Hepatitis C Virus Biotech Picks By The World's Largest Fund Managers

Editor's pick
Seeking Alpha
25 January 2012
New & experimental hepatitis C treatment

Entry Point for Hepatitis C Infection Identified

Editor's pick
University of Illinois press release
25 January 2012
New & experimental hepatitis C treatment

Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race

Editor's pick
Xconomy
25 January 2012
Hepatitis C treatment side-effects

Common side-effects of hepatitis C protease inhibitors: clinical management advice published

News
20 January 2012
New & experimental hepatitis C treatment

Achillion's Hep C Pipeline Likely Can't Compete

Editor's pick
BioMed Reports
19 January 2012
Pharmaceutical industry

Bristol-Myers Raised Offer 30% to Beat Competitor for Inhibitex

Editor's pick
Bloomberg Business Week
17 January 2012
New & experimental hepatitis C treatment

Idenix Reports Advancement of HCV Development Pipeline

Editor's pick
Idenix (press release)
11 January 2012
New & experimental hepatitis C treatment

Achillion Reports Clinical Data on Portfolio of HCV Protease Inhibitors

Editor's pick
Achillion (press release)
11 January 2012
Pharmaceutical industry

Merck Hepatitis C Drug May `Anchor' Future Worldwide Regimen

Editor's pick
Bloomberg
10 January 2012
Pharmaceutical industry

Bristol Buys Inhibitex for $2.5 Billion to Compete in Hepatitis

Editor's pick
Bloomberg BusinessWeek
9 January 2012
New & experimental hepatitis C treatment

Early guidance on use of hepatitis C protease inhibitors in HIV-co-infected patients

News
29 December 2011